Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction.
about
Elderly patients and inflammatory bowel diseaseLeucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazideMeasurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel diseaseGene expression and thiopurine metabolite profiling in inflammatory bowel disease - novel clues to drug targets and disease mechanisms?Therapeutic drug monitoring of antimetabolic cytotoxic drugs.Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy.Review article: monitoring for drug side-effects in inflammatory bowel disease.Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease.Review article: monitoring of immunomodulators in inflammatory bowel disease.Review article: practical management of inflammatory bowel disease patients taking immunomodulators.Review article: thiopurines in inflammatory bowel disease.Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease.PhRMA white paper on ADME pharmacogenomics.Evaluation of Physiological Activities of the Citron (Citrus junos Sieb. ex TANAKA) Seed Extracts.Implementation of TPMT testing.Thiopurines in Crohn's disease, is there something new?Monitoring and safety of azathioprine therapy in inflammatory bowel disease.Systematic review with meta-analysis: inflammatory bowel disease in the elderly.The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders.Prevalence of Non-Cytochrome P450-Mediated Metabolism in Food and Drug Administration-Approved Oral and Intravenous Drugs: 2006-2015.Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine.TPMT in the treatment of Crohn's disease with azathioprine.Use of allopurinol to optimize thiopurine immunomodulator efficacy in inflammatory bowel disease.Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease.TPMT in the treatment of inflammatory bowel disease with azathioprine.Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide.Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine.Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease.Bone marrow suppression in the setting of normal thiopurine methyltransferase phenotype testing.The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.Measurements of 6-thioguanine nucleotide levels with TPMT and NUDT15 genotyping in patients with Crohn's disease.Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine.Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn's Disease.Extrahepatic Drug-Metabolizing Enzymes and Their Significance
P2860
Q26768270-978F9255-25E2-419D-925E-C527C4A6092DQ28361611-7B01EF59-C033-4E4E-96D4-95EC4F0CECBEQ28361615-21E6BC92-1CCF-4E01-B0BF-84A1FDBEF8C0Q28486322-E2444223-E182-4D67-9F9B-49A3C58F0CB5Q33586713-8A8EEBE3-D0F2-4D24-9757-347BA0FF568EQ34112953-6436EA98-FB5E-43CC-8E64-AD37F9AB3BA1Q34585315-BEB56B9B-63BF-4A39-B846-31BF610ECE3AQ35221802-B62148B6-2FED-40D8-A264-0FDE14FAE37FQ35596702-A31E7FD2-C810-4D0B-B771-1EFD170F983FQ36041146-4FAD3DD3-074B-49CC-A02E-B5895F1C7726Q36166363-0E280DC5-7414-44E3-AAF8-029C6AC2DFB0Q36570796-53E018D5-EB90-4E1E-80A5-E5442B4992CCQ37149572-84009FC8-0A86-4F77-ACE3-318CC15D54D4Q37182212-40AD2C94-1D28-4FAC-9234-BD92C5B83DE4Q37481497-03FF9DC0-9521-4393-98E4-4561AFE79A64Q37678056-154E5F81-1C53-484E-8000-3D34AEA4795CQ37797517-43F1390D-87AA-4EC7-A6B3-F9CD4D6ABB2EQ38134756-0C5C7205-0E5B-4757-B4A7-E5F7A68ECEB8Q38176953-C739ED67-DE09-40DE-985B-C849012359B4Q38195146-B3EF682E-C21B-4697-899D-95D2334CED27Q38880368-A1150F28-643A-408E-AED8-6D56B60C8D5EQ40582133-D0146C4C-86A3-4220-9091-D07EB61C00E2Q41762842-5C955547-1CBC-4FA3-AD1B-33527FD158E7Q41985008-1D101072-F6D0-4025-A455-6329E4700394Q42477394-2CEA1293-99B6-4292-8BAD-B3B88ED2BF41Q43005696-8ACEE16A-30EF-4367-9D90-03FAEC6B1579Q43202350-4DC13204-2150-4A53-B3E1-B1F8F5A7B281Q43904255-69075694-256D-4869-AC54-77D9752EBDFFQ45713746-C6EDD920-F18D-4C4D-A987-409565E3FA81Q46023309-EBF034D8-7C68-4D63-912C-A41DF4D981F6Q46718223-C41F1390-D962-4A94-AC88-16EE112757CDQ47137978-23B9B3A5-216B-4239-8717-E0A923B7E690Q50448602-B2936E50-12E1-46C3-B449-93A2186A30C4Q50719037-5CF8F366-07E1-489B-B243-2704C6DA6ED9Q55162386-F4B7E7E4-4C0E-419B-8FA3-B22D4B782166Q57258718-CC7EC887-7904-472B-B47B-08C57D7B799A
P2860
Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Olsalazine and 6-mercaptopurin ...... ossible drug-drug interaction.
@en
Olsalazine and 6-mercaptopurin ...... ossible drug-drug interaction.
@nl
type
label
Olsalazine and 6-mercaptopurin ...... ossible drug-drug interaction.
@en
Olsalazine and 6-mercaptopurin ...... ossible drug-drug interaction.
@nl
prefLabel
Olsalazine and 6-mercaptopurin ...... ossible drug-drug interaction.
@en
Olsalazine and 6-mercaptopurin ...... ossible drug-drug interaction.
@nl
P2093
P1476
Olsalazine and 6-mercaptopurin ...... ossible drug-drug interaction.
@en
P2093
Nierenberg DW
Otterness DM
Szumlanski CL
P304
P356
10.1016/S0009-9236(97)90125-9
P407
P577
1997-10-01T00:00:00Z